Therefore, we hypothesized high expression of CSE1L and AURK pathway genes may identify p53 WT NSCLC cells most susceptible to mocetinostat or the clinically relevant mocetinostat plus PTX combination. The gene discussed is TP53; the disease is non-small cell lung carcinoma.